TrialInvestigational new drugs2012

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.

Jason E Faris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.